title: Toll-like receptor 3 stimulation promotes Ro52/TRIM21 synthesis and nuclear redistribution in salivary gland epithelial cells, partially via type I interferon pathway.
abstract: Up-regulated expression of Ro52/tripartite motif-containing protein 21 (TRIM21), Ro60/TROVE domain family, member 2 (TROVE2) and lupus LA protein/Sjögren's syndrome antigen B (La/SSB) autoantigens has been described in the salivary gland epithelial cells (SGEC) of patients with Sjögren's syndrome (SS). SGECs, the key regulators of autoimmune SS responses, express high levels of surface functional Toll-like receptor (TLR)-3, whereas Ro52/TRIM21 negatively regulates TLR-3-mediated inflammation. Herein, we investigated the effect of TLR-3-signalling on the expression of Ro52/TRIM21, as well as Ro60/TROVE2 and La/SSB autoantigens, by SGECs. The effect of TLR-3 or TLR-4 stimulation on autoantigen expression was evaluated by polyI:C or lipopolysaccharide (LPS) treatment, respectively, of SGEC lines (10 from SS patients, 12 from non-SS controls) or HeLa cells, followed by analysis of mRNA and protein expression. PolyI:C, but not LPS, resulted in a two-step induction of Ro52/TRIM21 mRNA expression by SGECs, a 12-fold increment at 6 h followed by a 2.5-fold increment at 24-48 h, whereas it induced a late two-fold up-regulation of Ro60/TROVE2 and La/SSB mRNAs at 48 h. Although protein expression levels were not affected significantly, the late up-regulation of Ro52/TRIM21 mRNA was accompanied by protein redistribution, from nucleolar-like pattern to multiple coarse dots spanning throughout the nucleus. These late phenomena were mediated significantly by interferon (IFN)-β production, as attested by cognate secretion and specific inhibition experiments and associated with IFN regulatory factor (IRF)3 degradation. TLR-3-signalling had similar effects on SGECs obtained from SS patients and controls, whereas it did not affect the expression of these autoantigens in HeLa cells. TLR-3 signalling regulates the expression of autoantigens by SGECs, implicating innate immunity pathways in their over-expression in inflamed tissues and possibly in their exposure to the immune system.
authors.affiliation: Department of Pathophysiology, School of Medicine, National University of Athens, Athens, Greece.
authors.forename: N C
authors.initials: NC
authors.lastname: Kyriakidis
authors.forename: E K
authors.initials: EK
authors.lastname: Kapsogeorgou
authors.forename: V C
authors.initials: VC
authors.lastname: Gourzi
authors.forename: O D
authors.initials: OD
authors.lastname: Konsta
authors.forename: G E
authors.initials: GE
authors.lastname: Baltatzis
authors.forename: A G
authors.initials: AG
authors.lastname: Tzioufas
mesh_terms: D017209:Apoptosis; D002467:Cell Nucleus / Q000378:metabolism*; D002478:Cells, Cultured; D004847:Epithelial Cells / Q000378:metabolism; D006367:HeLa Cells; D006801:Humans; D007370:Interferon Type I / Q000502:physiology*; D016899:Interferon-beta / Q000096:biosynthesis; D011070:Poly I-C / Q000494:pharmacology; D012261:Ribonucleoproteins / Q000096:biosynthesis* / Q000235:genetics; D012469:Salivary Glands / Q000378:metabolism*; D015398:Signal Transduction; D012859:Sjogren's Syndrome / Q000209:etiology; D051196:Toll-Like Receptor 3 / Q000502:physiology*; D000099207:SS-A Antigen
chemical_list: D007370:Interferon Type I; D016899:Interferon-beta; D011070:Poly I-C; D012261:Ribonucleoproteins; D051196:Toll-Like Receptor 3; D000099207:SS-A Antigen; C495344:TLR3 protein, human
keywords: Ro52/TRIM21 autoantigen; Sjögren's syndrome; TLR-3; salivary gland epithelial cells; type I interferons
references.citation: Eur J Oral Sci. 2002 Feb;110(1):21-30
references.pmid: 11878756
references.citation: J Exp Med. 2009 Aug 3;206(8):1661-71
references.pmid: 19635858
references.citation: PLoS One. 2013 Oct 17;8(10):e77605
references.pmid: 24147035
references.citation: Mol Med. 2010 Jan-Feb;16(1-2):19-26
references.pmid: 19838329
references.citation: Scand J Immunol. 2002 Nov;56(5):456-69
references.pmid: 12410795
references.citation: Clin Immunol Immunopathol. 1998 Aug;88(2):133-41
references.pmid: 9714690
references.citation: Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20446-51
references.pmid: 19074283
references.citation: J Clin Immunol. 2008 May;28(3):220-31
references.pmid: 18071879
references.citation: Exp Cell Res. 2008 Dec 10;314(20):3605-13
references.pmid: 18845142
references.citation: Clin Exp Immunol. 2000 Sep;121(3):551-6
references.pmid: 10971524
references.citation: J Immunol. 2001 Mar 1;166(5):3107-13
references.pmid: 11207262
references.citation: J Immunol. 2006 May 15;176(10):6277-85
references.pmid: 16670339
references.citation: J Oral Pathol Med. 2013 Jan;42(1):66-72
references.pmid: 22672212
references.citation: Am J Physiol. 1996 Jun;270(6 Pt 1):C1743-50
references.pmid: 8764158
references.citation: Oral Dis. 2011 Nov;17(8):801-7
references.pmid: 21815968
references.citation: J Autoimmun. 1999 Dec;13(4):429-34
references.pmid: 10585759
references.citation: Arthritis Rheum. 1997 Jan;40(1):87-97
references.pmid: 9008604
references.citation: J Rheumatol. 1997 Aug;24(8):1552-7
references.pmid: 9263150
references.citation: J Autoimmun. 2012 Aug;39(1-2):77-82
references.pmid: 22402340
references.citation: Clin Immunol Immunopathol. 1994 Aug;72(2):162-5
references.pmid: 8050187
references.citation: J Oral Pathol Med. 2009 Jan;38(1):42-7
references.pmid: 19192049
references.citation: Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2770-5
references.pmid: 16477017
references.citation: N Engl J Med. 1979 Jul 5;301(1):5-8
references.pmid: 449915
references.citation: J Autoimmun. 2012 Aug;39(1-2):4-8
references.pmid: 22326205
references.citation: J Autoimmun. 2010 Nov;35(3):212-8
references.pmid: 20685081
references.citation: J Immunol. 2009 Mar 15;182(6):3782-92
references.pmid: 19265157
references.citation: Nature. 2001 Oct 18;413(6857):732-8
references.pmid: 11607032
references.citation: Immunity. 2013 Mar 21;38(3):450-60
references.pmid: 23453632
references.citation: J Immunol. 2000 Sep 15;165(6):3519-26
references.pmid: 10975873
references.citation: Arthritis Rheum. 2006 May;54(5):1557-67
references.pmid: 16645989
references.citation: Clin Exp Immunol. 2007 Mar;147(3):497-503
references.pmid: 17302899
references.citation: J Autoimmun. 2010 Jun;34(4):400-7
references.pmid: 19889514
references.citation: Ann Rheum Dis. 2010 Jun;69(6):1235-8
references.pmid: 19914903
references.citation: Crit Rev Clin Lab Sci. 2006;43(3):203-48
references.pmid: 16574554
references.citation: Biochem Biophys Res Commun. 2006 Jan 6;339(1):415-21
references.pmid: 16297862
references.citation: J Autoimmun. 2010 Nov;35(3):225-31
references.pmid: 20674271
references.citation: Immunology. 2002 Jun;106(2):246-56
references.pmid: 12047754
references.citation: Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17609-14
references.pmid: 23045702
references.citation: J Exp Med. 1995 Apr 1;181(4):1557-61
references.pmid: 7699336
references.citation: Methods. 2001 Dec;25(4):402-8
references.pmid: 11846609
references.citation: Arthritis Rheum. 1998 Dec;41(12):2238-48
references.pmid: 9870881
references.citation: Ann Rheum Dis. 2002 Jun;61(6):554-8
references.pmid: 12006334
references.citation: Arthritis Rheum. 2005 Apr;52(4):1185-95
references.pmid: 15818675
references.citation: Arthritis Rheum. 2005 May;52(5):1517-21
references.pmid: 15880835
references.citation: Rheumatology (Oxford). 2002 Mar;41(3):338-42
references.pmid: 11934973